<div><i>References:</i></div><div>1. De Paolis E, De Bonis M, Concolino P, Piermattei A, Fagotti A, Urbani
A, et al. Droplet digital PCR for large genomic rearrangements
detection: A promising strategy in tissue BRCA1 testing. Clin Chim Acta.
2021 Feb;513:17-24.</div><div>2. Bekos C, Grimm C, Kranawetter M, Polterauer S, Oberndorfer F, Tan Y,
et al. Reliability of Tumor Testing Compared to Germline Testing for
Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian
Cancer. J Pers Med. 2021 Jun;11(7):593.</div><div>3. Ellison G, Ahdesmäki M, Luke S, Waring PM, Wallace A, Wright R, et
al. An evaluation of the challenges to developing tumor BRCA1 and BRCA2
testing methodologies for clinical practice. Hum Mutat. 2018
Mar;39(3):394-405.</div><div>4. Kordes M, Tamborero D, Lagerstedt-Robinson K, Yachnin J, Rosenquist
R, Löhr J-M, et al. Discordant Reporting of a Previously Undescribed
Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient
With Pancreatic Adenocarcinoma. JCO Precision Oncology 2021
May;5:974-980.</div><div>5. Gourley C. Gene sequencing in ovarian cancer: continually moving
targets. BJOG. 2021 Oct;10.1111/1471-0528.16978.</div><div>6. Fumagalli C, Tomao F, Betella I, Rappa A, Calvello M, Bonanni B, et
al. Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The
Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.
Cancers (Basel). 2019 Oct;11(11):1641.</div><div>7. Peixoto A, Pinto P, Guerra J, Pinheiro M, Santos C, Pinto C, et al.
Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian
Cancer Patients in the Context of Strong Founder Effects. Front Oncol.
2020 Jul;10:1318.</div><div>8. Care M, McCuaig J, Clarke B, Grenier S, Kim RH, Rouzbahman M, et al.
Tumor and germline next generation sequencing in high grade serous
cancer: experience from a large population-based testing program. Mol
Oncol. 2021 Jan; 15(1):80-90.</div><div>9. Rivera D, Paudice M, Gismondi V, Anselmi G, Vellone VG, Varesco L, et
al, Implementing NGS-based BRCA tumour tissue testing in FFPE ovarian
carcinoma specimens: hints from a real-life experience within the
framework of expert recommendations. J Clin Pathol. 2021 Sep;
74(9):596-603.</div><div>10. Kim SI, Lee M, Seung Kim H, Hoon Chung H, Kim J, Park NH, et al.
Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical
Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer:
Over a Decade of Experience in a Single Institution in Korea. Cancer Res
Treat. 2020 Oct; 52(4):1229-1241.</div><div>11. Moore K, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M, et
al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced
Ovarian Cancer. N Engl J Med. 2018 Dec; 379(26):2495-2505.</div><div>12. Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ. Mutation
landscape of germline and somatic BRCA1/2 in patients with high-grade
serous ovarian cancer. BMC Cancer. 2020 Mar;20(1):204.</div><div>13. Frugtniet B, Morgan S, Murray A, Palmer-Smith S, White R, Jones R,
et al. The detection of germline and somatic BRCA1/2 genetic variants
through parallel testing of patients with high-grade serous ovarian
cancer: a national retrospective audit. BJOG. 2021
Oct;10.1111/1471-0528.16975</div><div>14. Capoluongo E, Ellison G, López-Guerrero JA, Penault-Llorca F,
Ligtenberg MJL, Banerjee S. et al. Guidance Statement On BRCA1/2 Tumor
Testing in Ovarian Cancer Patients. Semin Oncol. 2017 Jun;
44(3):187-197.</div><div>15. Lincoln SE, Nussbaum RL, Kurian AW, Nielsen SM, Das K, Michalski S,
et al. Yield and utility of germline testing following tumor sequencing
in patients with cancer. JAMA Netw Open. 2020 Oct;3(10):e2019452.</div><div>16. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al.
Standards and guidelines for the interpretation of sequence variants: a
joint consensus recommendation of the American College of Medical
Genetics and Genomics and the Association for Molecular Pathology. Genet
Med. 2015 May;17(5):405-24.</div><div>17. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al.
Standards and Guidelines for the Interpretation and Reporting of
Sequence Variants in Cancer: A Joint Consensus Recommendation of the
Association for Molecular Pathology, American Society of Clinical
Oncology, and College of American Pathologists. J Mol Diagn. 2017 Jan;
19(1):4-23.</div><div>18. Moody EW, Vagher J, Espinel W, Goldgar D, Hagerty KJ, Gammon A.
Comparison of Somatic and Germline Variant Interpretation in Hereditary
Cancer Genes. JCO Precision Oncology 2019 Oct:3, 1-8.</div><div>19. De Paolis E, Pietragalla A, De Bonis M, Fagotti A, Urbani A, Scambia
G, et al. The BRCA1 c.788G &gt; T (NM_007294.4) variant in a
high grade serous ovarian cancer (HGSOC) patient: foods for thought. Mol
Biol Rep. 2021 Mar; 48(3):2985-2992.</div>